Research from the WHI Estrogen-plus-Progestin study has shown that women taking combined hormone therapy had the following benefits: One-third lower risk of colorectal cancer than women taking the placebo. In absolute terms, this meant 10 cases of colorectal cancer per 10,000 women per year who took hormone therapy compared with 16 cases of colorectal cancer per 10,000 women per year who took the placebo. In the initial study report, women taking combined hormone therapy had a lower risk of colorectal cancer than women who took the placebo.However, the colorectal tumors that arose in the combined hormone therapy group were more advanced at detection than those in the placebo group. There was no difference in either the risk of colorectal cancer or the stage of disease at diagnosis between women who took estrogen alone and those who took the placebo. However, a subsequent analysis of the WHI trials found no strong evidence that either estrogen alone or estrogen plus progestin had any effect on the risk of colorectal cancer, tumor stage at diagnosis, or death from colorectal cancer.
This answer is based on source information from the National Cancer Institute.
Research from the WHI Estrogen-plus-Progestin study has shown that
women taking combined hormone therapy had the following benefits:
One-third lower risk of colorectal cancer than women taking the
placebo. In absolute terms, this meant 10...
More
Riverside Health System answered:Research from the WHI Estrogen-plus-Progestin study has shown that women taking combined hormone therapy had the following benefits: One-third lower risk of colorectal cancer than women taking the placebo. In absolute terms, this meant 10 cases of colorectal cancer per 10,000 women per year who took hormone therapy compared with 16 cases of colorectal cancer per 10,000 women per year who took the placebo. In the initial study report, women taking combined hormone therapy had a lower risk of colorectal cancer than women who took the placebo.However, the colorectal tumors that arose in the combined hormone therapy group were more advanced at detection than those in the placebo group. There was no difference in either the risk of colorectal cancer or the stage of disease at diagnosis between women who took estrogen alone and those who took the placebo. However, a subsequent analysis of the WHI trials found no strong evidence that either estrogen alone or estrogen plus progestin had any effect on the risk of colorectal cancer, tumor stage at diagnosis, or death from colorectal cancer.
